More recently, it has been shown that the inhibition of BRD4 activity by its selective inhibitors displays therapeutic potential for liver cancer, gastric cancer, pituitary adenoma, aeroallergen-induced inflammation, and airway remodeling (26–28). This evidence concerns the gene BRD4 and gastric cancer.